Celltrion is set to participate in the 2026 BIO International Convention (BIO USA) next week in San Diego, California. The company aims to showcase its artificial intelligence (AI)-driven drug development capabilities and next-generation pipeline to the global market while securing future growth opportunities through expanded international partnerships.

Since 2010, Celltrion has been a consistent presence at BIO USA for 17 consecutive years, broadening its network with global pharmaceutical and biotech firms. This year, the company will operate a standalone booth spanning approximately 139 square meters (about 1,496 square feet). Here, Celltrion will present its next-generation growth strategies and drug development prowess to the global market, while also engaging in business meetings and technology exchanges with competitive firms.

Celltrion plans to leverage this platform not just for corporate promotion, but as a global business hub to concretize its future growth strategies. Building on its extensive experience in biosimilars research, development, production, and commercialization, the company aims to expand collaboration opportunities with global partners in cutting-edge areas such as AI-driven drug development, antibody-drug conjugates (ADCs), and multi-specific antibodies.

At this year's event, Celltrion will aggressively promote its AI-powered drug development capabilities and business strategies. Capitalizing on its prime location in the AI Zone, the company plans to showcase several technologies to global visitors, including AI-based new target discovery and portfolio expansion, next-generation multi-antibody design technology, in silico developability assessment, and its data-driven research platform, the Healthcare Intelligence Bank.

Celltrion is pioneering research that harnesses AI to design and evaluate the physicochemical properties, manufacturability, and immunogenicity of antibody candidates. This approach enables early selection of candidates with high potential for clinical success.

By implementing these AI-driven strategies, Celltrion is enhancing the efficiency of its drug development process, shortening timelines, and increasing success rates. The company is also developing a multimodal AI-based research platform to integrate and analyze diverse data sets, advancing its data-driven decision-making in drug development.

Alongside its AI-driven research and development (R&D) strategy, Celltrion will prominently feature its next-generation drug pipeline, including ADCs and multi-specific antibodies, at this year's event.

The company is accelerating the development of ADCs and multi-specific antibodies as core growth drivers for the future. During BIO USA, Celltrion plans to actively present its technologies and pipeline progress to global pharmaceutical companies, biotech firms, and investors.

Expanding global partnerships is another key objective for Celltrion at BIO USA. Throughout the event, the company will engage in numerous strategic meetings with global pharmaceutical and biotech firms to identify various business opportunities, including licensing deals, co-development agreements, and technological collaborations, all aimed at expanding its marketable and competitive biosimilar and novel drug pipelines.

Furthermore, Celltrion aims to bolster its manufacturing and business competitiveness through meetings with suppliers to enhance production efficiency and technical capabilities, as well as by forging global partnerships that align with its core business areas.

A Celltrion spokesperson stated that BIO USA is the premier global business platform where biotech companies, investors, and technology partners from around the world converge. Through this event, Celltrion plans to actively communicate its future vision and technological prowess as it evolves from a biosimilar company to a global innovator in drug development.

The spokesperson added tha it will leverage our next-generation growth drivers, including the AI-driven drug development platform, ADCs, and multi-specific antibodies, to expand global partnerships. They're actively seeking meaningful business opportunities that will contribute to Celltrion's long-term growth and enhance our corporate value.

This year's BIO USA is expected to serve as a barometer for the global biotech industry, transcending mere technology showcases. Key topics such as the validation of AI-driven drug development results, restructuring of global supply chains, and the recovery of investment markets have emerged as central issues. Consequently, domestic companies are gearing up to seize opportunities for technology exports, joint research initiatives, and investment attraction.

Celltrion is set to participate in the 2026 BIO International Convention (BIO USA) next we …

How Celltrion Plans to Revolutionize Drug Development with AI at Bio USA 2026